There’s been no shortage of blockbuster deals as the J.P. Morgan Healthcare Conference kicked off Monday in San Francisco, and now Eli Lilly has joined the fray, setting down $1 billion up front for ...

Metronomic capecitabine combined with an aromatase inhibitor extends median progression-free survival to 20.9 months compared with 11.9 months for aromatase inhibitor alone in hormone receptor ...

As our knowledge about aromatase inhibitors and their side effects has expanded, questions remain unanswered with regards to their influence on cognition. Future study designs evaluating cognitive ...